DIO TREE Overview
Dio Tree develops a novel small molecule for the treatment of ovarian cancer. The technology is based on inhibition of the enzyme DIO3, which is a major driver in many types of cancer, specifically ovarian cancer. The technology involves a series of small molecules targeting DIO3.
Cumulative Funding Raised Over Time ($)
$400KDec 2022
Latest News
growth-positive
"Imagine a scenario where a single drug could alter the course of a patient's battle with cancer" | CTech
Dio Tree, a company developing a new drug to treat ovarian cancer, has raised $400,000 in a seed funding round. The investment was led by the Israeli Innovation Authority and NGT fund. The company, which currently has three employees, plans to use the funds primarily for research and development. The drug, which is still in the research and development phase, could potentially be expanded to treat other types of cancer, including breast, lung, and pancreas. Clinical trials are expected to begin within two years, with the treatment potentially available to the public in about five years.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $1.05M |
| Last funding | $650K |
| Stage | Pre-Seed |
| Rounds | 2 |
| Investors | 2 |
Team Members
3
Employees: 1-10
Web & Social Links
| Website | www.dio-tree.com/ |
Locations
Wadi el-Haj St 13, Nazareth, Israel
Photos & Videos
No files yet
DIO TREE Business
Business models
B2B2C
Product stage
R&D
Employees
1-10
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesHealthcarePatientsLife SciencesBiotechnologyCore Technology
BiologicalsMoleculesTags (7)
healthcareoncologycancerfemtechbiotechnologywomen-healthbiopharmaceuticalDIO TREE Financials
$1.05M
Total funding
Undisclosed
Capital raised
$650K
Last funding
Pre-Seed
Funding stage
2
Total rounds
2
Investors
Cumulative Funding Raised Over Time ($)
$400KDec 2022
Private Equity Funding
Pre-Seed
Dec 2022
$400K
NGT HealthCare II (Lead)
,
Israel Innovation Authority
Non-Equity Funding
GrantEvent
Jan 2024
$650K
Israel Innovation Authority
DIO TREE Lifecycle
Cumulative Funding Raised Over Time
$400KDec 2022
All Events
Pre-Seed
Dec 2022
$400K
NGT HealthCare II (Lead)
,
Israel Innovation Authority
GrantEvent
Jan 2024
$650K
Israel Innovation Authority
DIO TREE News
1 article
growth-positive
"Imagine a scenario where a single drug could alter the course of a patient's battle with cancer" | CTech
Dio Tree, a company developing a new drug to treat ovarian cancer, has raised $400,000 in a seed funding round. The investment was led by the Israeli Innovation Authority and NGT fund. The company, which currently has three employees, plans to use the funds primarily for research and development. The drug, which is still in the research and development phase, could potentially be expanded to treat other types of cancer, including breast, lung, and pancreas. Clinical trials are expected to begin within two years, with the treatment potentially available to the public in about five years.
Investment
DIO TREE Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 4 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 10 classification IDs that could be used for matching.
DIO TREE Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 89/100 |
| Missing | video or image, markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 516693314 |
| Phone | +972526283780 |
| Creator | Ortal Wein |
| Creator email | ortalw@sncentral.org |
| Last updater | Matan Eblagon |
| Updater email | matane@sncentral.org |
| Last update | 2023-08-10T00:00:00.000Z |
| Created | 2023-03-21T00:00:00.000Z |